CN104800838B - MUC1‑Fc多肽疫苗及其制备方法和应用 - Google Patents
MUC1‑Fc多肽疫苗及其制备方法和应用 Download PDFInfo
- Publication number
- CN104800838B CN104800838B CN201510175146.4A CN201510175146A CN104800838B CN 104800838 B CN104800838 B CN 104800838B CN 201510175146 A CN201510175146 A CN 201510175146A CN 104800838 B CN104800838 B CN 104800838B
- Authority
- CN
- China
- Prior art keywords
- muc1
- immunoglobulin
- section
- vaccine
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 90
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 79
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 79
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 title claims abstract description 58
- 102100034256 Mucin-1 Human genes 0.000 title claims abstract description 58
- 229960005486 vaccine Drugs 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000000427 antigen Substances 0.000 claims abstract description 54
- 102000036639 antigens Human genes 0.000 claims abstract description 54
- 108091007433 antigens Proteins 0.000 claims abstract description 54
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 40
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 40
- 230000014509 gene expression Effects 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 241000588724 Escherichia coli Species 0.000 claims abstract description 7
- 230000006801 homologous recombination Effects 0.000 claims description 7
- 238000002744 homologous recombination Methods 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001610 polycaprolactone Polymers 0.000 claims description 6
- 239000004632 polycaprolactone Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000035558 fertility Effects 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000969 carrier Substances 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract description 4
- 239000002502 liposome Substances 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000001665 lethal effect Effects 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000002086 nanomaterial Substances 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (12)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510175146.4A CN104800838B (zh) | 2015-04-14 | 2015-04-14 | MUC1‑Fc多肽疫苗及其制备方法和应用 |
PCT/CN2015/092338 WO2016165301A1 (zh) | 2015-04-14 | 2015-10-20 | MUC1-Fc多肽疫苗及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510175146.4A CN104800838B (zh) | 2015-04-14 | 2015-04-14 | MUC1‑Fc多肽疫苗及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104800838A CN104800838A (zh) | 2015-07-29 |
CN104800838B true CN104800838B (zh) | 2018-01-09 |
Family
ID=53686316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510175146.4A Active CN104800838B (zh) | 2015-04-14 | 2015-04-14 | MUC1‑Fc多肽疫苗及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104800838B (zh) |
WO (1) | WO2016165301A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
CN104800838B (zh) * | 2015-04-14 | 2018-01-09 | 深圳市中联生物科技开发有限公司 | MUC1‑Fc多肽疫苗及其制备方法和应用 |
CN109689692B (zh) * | 2016-06-22 | 2021-11-12 | 本康生物制药(深圳)有限公司 | 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用 |
CN108743939B (zh) * | 2018-08-07 | 2021-08-20 | 中国医学科学院生物医学工程研究所 | 共载抗原、mpla与imq的阳离子磷脂-聚合物杂化纳米粒疫苗佐剂及制备方法与应用 |
CN114028539B (zh) * | 2021-09-13 | 2024-04-26 | 北京大学 | 粘蛋白1在抑制冠状病毒中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8034351B2 (en) * | 2002-04-22 | 2011-10-11 | Recopharma Ab | Mucin fusion polypeptide vaccines, compositions and methods of use thereof |
CN1315536C (zh) * | 2002-09-13 | 2007-05-16 | 李进 | 肿瘤抗原疫苗及其制备方法和疫苗组合物 |
AU2007208218A1 (en) * | 2006-01-23 | 2007-08-02 | Recopharma Ab | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof |
CN103372205A (zh) * | 2012-04-26 | 2013-10-30 | 上海复和泰生物技术有限公司 | 糖基化muc1抗原致敏的肿瘤树突状细胞疫苗制备方法 |
CN104800838B (zh) * | 2015-04-14 | 2018-01-09 | 深圳市中联生物科技开发有限公司 | MUC1‑Fc多肽疫苗及其制备方法和应用 |
-
2015
- 2015-04-14 CN CN201510175146.4A patent/CN104800838B/zh active Active
- 2015-10-20 WO PCT/CN2015/092338 patent/WO2016165301A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN104800838A (zh) | 2015-07-29 |
WO2016165301A1 (zh) | 2016-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104800838B (zh) | MUC1‑Fc多肽疫苗及其制备方法和应用 | |
JP4658423B2 (ja) | Her−2タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド | |
JP7232825B2 (ja) | 腫瘍関連抗原エピトープの微生物叢(microbiota)配列変異体 | |
Ghasparian et al. | Engineered Synthetic Virus‐Like Particles and Their Use in Vaccine Delivery | |
CN109584966B (zh) | 一种肿瘤通用疫苗的设计方法及胰腺癌通用疫苗 | |
WO2013178079A1 (zh) | 一种肿瘤疫苗及其制备方法 | |
Dai et al. | Immune-regulating bimetallic metal-organic framework nanoparticles designed for cancer immunotherapy | |
Zhong et al. | A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice | |
CN109512799A (zh) | 一种装载抗肿瘤药物的纳米药物载体、其制备方法及应用 | |
Chen et al. | Chitosan nanoparticles based nanovaccines for cancer immunotherapy | |
WO2018065628A2 (en) | Microbiota sequence variants of tumor-related antigenic epitopes | |
Stockinger | Capacity of antigen uptake by B cells, fibroblasts or macrophages determines efficiency of presentation of a soluble self antigen (C5) to T lymphocytes | |
Kavunja et al. | Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice | |
JP7103726B2 (ja) | 医薬組成物、脂質ベシクル粒子の分粒を含む調製のための方法、及びそれらの使用 | |
CN101643497A (zh) | Lmp2a蛋白来源的hla-a2限制性表位多肽及其用途 | |
JP2020526530A (ja) | 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用 | |
CN107058231A (zh) | 携带融合蛋白基因的重组腺病毒及其制备方法和应用 | |
Biri-Kovács et al. | Peptide vaccines in melanoma: chemical approaches towards improved immunotherapeutic efficacy | |
CN110269931B (zh) | 一种水凝胶肿瘤疫苗的制备方法以及由其制备的水凝胶肿瘤疫苗和其用途 | |
Shi et al. | Development of novel self‐assembled vaccines based on tumour‐specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating CD8+ T cells and enhancing their function | |
Dong et al. | A comparison study of iTEP nanoparticle-based CTL vaccine carriers revealed a surprise relationship between the stability and efficiency of the carriers | |
Eskandari et al. | Influence of physicochemical properties of lipopeptide adjuvants on the immune response: a rationale for engineering a potent vaccine | |
CN103933557B (zh) | 一种神经胶质瘤的双向调节治疗性疫苗及其制备方法 | |
Shariat et al. | Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects | |
CN105481985A (zh) | 一种热休克蛋白70功能肽与甲胎蛋白抗原表位肽复合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160316 Address after: Nanshan District city of Shenzhen province Guangdong Taoyuan street 518055 Liuxian Avenue No. 1183 Nanshan Valley Innovation Industrial Park Comprehensive Service Building 506-508 Applicant after: Shenzhen Zhonglian Biological Technology Development Co., Ltd. Address before: 518055, Shenzhen, Guangdong, Nanshan District, Taoyuan street, Tian Lao Industrial Zone, A building, two West Applicant before: Su Jing |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200122 Address after: 518000, Shenzhen, Guangdong, Nanshan District province Taoyuan street, Tian Lao industrial A District 9, west of the two floor Patentee after: BENHEALTH BIOPHARMACEUTIC (SHENZHEN) Co.,Ltd. Address before: Nanshan District city of Shenzhen province Guangdong Taoyuan street 518055 Liuxian Avenue No. 1183 Nanshan Valley Innovation Industrial Park Comprehensive Service Building 506-508 Patentee before: SHENZHEN ZHONGLIAN BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |